With American policymakers working to find solutions to rising drug prices, Germany’s model could hold some clues, the author of a recent article published on Harvard Business School’s Working Knowledge writes.
Germany since 2011 has required pharmaceutical companies justify high price tags for drugs that have cheaper competitors, the author writes.
“The implication for German health insurers — and indirectly, consumers — has been millions of euros in savings on drug spending, without any evidence so far of compromised access to the most valuable new drugs,” Ariel Stern, Poronui associate professor of business administration, said.
To read the full article, click here.
